(vianews) - equasens (eqs.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| equasens (eqs.pa) | €74.70 | 1.78% | 27.25% |
| ipsen (ipn.pa) | €118.80 | 1.02% | 12.52% |
| virbac (virp.pa) | €271.50 | 0.51% | 13.8% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. equasens (eqs.pa)
1.78% forward dividend yield and 27.25% return on equity
equasens société anonyme provides healthcare it solutions in europe. it offers id. patient, a business software; id. mobility, a back-office management software; pandalab pro, an instant messaging solution; id. vente, an has-certified drug database; id. commande, an order management module; dispensing robots; services ségur id; id. dosage, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; visiodroits module; and website connector. the company also provides id. desk, an informative and interactive dashboard; id. up!, a real-time monitoring and control application of id management software; id. easyq, a queue management solution; miaterapia; id. show, an application for managing real-time communications on pharmacy screens; pharmaweb; tsgatepro; lmo, a dispensary business software; and lgo, a dispensary management software. in addition, it offers domilink had software; mobisoins mobility tool; memorialis, support software for alzheimer's monitoring teams; hospilink, an hospital information system applications; hospilink dpi, a computerized patient file; hospilink lookup big data; enephro solutions; noviacare solutions; kap&link2, a contact chip card reader terminal and nfc reader; es-kap-ad, a connected nomadic tool incorporating software; kap-inside, a mobile terminal; and ti-kap allowing access to contact and contactless cards. further, the company provides authenticator, a patented authentication system; kap'teur by kapelse, a patented universal sensor; expressvitale; médistory, that automates the transfer of invoicing to the healthcare professional's accounting. additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. the company was incorporated in 1996 and is headquartered in villers-les-nancy, france. equasens société anonyme is a subsidiary of marque verte sante.
earnings per share
as for profitability, equasens has a trailing twelve months eps of €3.05.
pe ratio
equasens has a trailing twelve months price to earnings ratio of 24.49. meaning, the purchaser of the share is investing €24.49 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.25%.
more news about equasens.
2. ipsen (ipn.pa)
1.02% forward dividend yield and 12.52% return on equity
ipsen s.a. operates as a biopharmaceutical company worldwide. the company provides drugs in the areas of oncology, neuroscience, and rare diseases. it offers somatuline for neuroendocrine tumors and acromegaly; dysport for motor muscular disorders and medical aesthetics; decapeptyl for the treatment of advanced metastatic prostate cancer; cabometyx for renal cell and second-line hepatocellular carcinoma; onivyde for second-line metastatic pancreatic cancer; and tazverik to treat third-line follicular lymphoma. the company also provides nutropinaq for growth failure in children due to growth hormone (gh) deficiency, turner syndrome or chronic renal insufficiency, and gh deficiency in adults; and increlex for growth failure in children and adolescents. in addition, it offers xermelo for the treatment of carcinoid syndrome; and cometriq to treat medullary thyroid cancer. ipsen s.a. has agreements with debiopharm; exelixis; galderma; blueprint medicines; tersera therapeutics; rhythm pharmaceuticals; teijin; schwabe; bakx therapeutics inc.; and exicure. the company was founded in 1929 and is headquartered in boulogne-billancourt, france.
earnings per share
as for profitability, ipsen has a trailing twelve months eps of €4.9.
pe ratio
ipsen has a trailing twelve months price to earnings ratio of 24.24. meaning, the purchaser of the share is investing €24.24 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.52%.
more news about ipsen.
3. virbac (virp.pa)
0.51% forward dividend yield and 13.8% return on equity
virbac sa manufactures and sells a range of products and services for companion animals and farm animals in france, europe, latin america, north america, asia, pacific, and africa and the middle east. the company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. it serves veterinarians, farmers, and pet owners. virbac sa was founded in 1968 and is headquartered in carros, france.
earnings per share
as for profitability, virbac has a trailing twelve months eps of €14.39.
pe ratio
virbac has a trailing twelve months price to earnings ratio of 18.87. meaning, the purchaser of the share is investing €18.87 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.8%.
more news about virbac.